Annexin Pharmaceuticals AB (publ) Stock Nasdaq Stockholm
Equities
Biotechnology & Medical Research
Sales 2024 * | - | Sales 2025 * | 39.6M 3.64M | Capitalization | 93.92M 8.63M |
---|---|---|---|---|---|
Net income 2024 * | -52M -4.78M | Net income 2025 * | -16M -1.47M | EV / Sales 2024 * | - |
Net cash position 2024 * | 18.4M 1.69M | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.37 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 21.9% |
Managers | Title | Age | Since |
---|---|---|---|
Anna Frostegård
FOU | Founder | 51 | 13-12-31 |
Chief Executive Officer | 63 | 17-12-31 | |
Director of Finance/CFO | 53 | 23-04-10 |
Members of the board | Title | Age | Since |
---|---|---|---|
Uli Alf Hacksell
CHM | Chairman | 74 | 20-12-31 |
Mårten Österlund
BRD | Director/Board Member | 67 | 20-12-31 |
Chief Executive Officer | 63 | 17-12-31 |
1st Jan change | Capi. | |
---|---|---|
+2.49% | 96.73B | |
-0.09% | 21.31B | |
-16.61% | 21.21B | |
-5.80% | 18.79B | |
-42.14% | 16.37B | |
-27.40% | 13.68B | |
+1.44% | 13.44B | |
+21.29% | 10.98B | |
-21.79% | 8.56B |